Trial Profile
A Bioequivalence and Food Effect Study of Evacetrapib Evaluating a Single Tablet Compared to Two Tablets in Healthy Japanese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Oct 2018
Price :
$35
*
At a glance
- Drugs Evacetrapib (Primary)
- Indications Atherosclerosis; Cardiovascular disorders; Dyslipidaemias
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 11 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov.
- 19 Mar 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov.